Bioresonance, an alternative therapy for mild and moderate depression

Muresan,Daniela; Voidăzan,Septimiu; Salcudean,Andreea; Bodo,Cristina Raluca; Grecu,Iosif Gabos

doi:10.3892/etm.2022.11190

Bioresonance, an alternative therapy for mild and moderate depression

Authors:
- Daniela Muresan
- Septimiu Voidăzan
- Andreea Salcudean
- Cristina Raluca Bodo
- Iosif Gabos Grecu
View Affiliations

Affiliations: Doctoral School of Medicine and Pharmacy, Department of Medicine, ‘George Emil Palade’ University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania, Department of Epidemiology, ‘George Emil Palade’ University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania, Department of Ethics and Social Sciences, ‘George Emil Palade’ University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania, Psychiatric Clinic No. 2, Mures County Hospital, 540142 Targu Mures, Romania, Senior Psychiatrist Psychiatric Clinic No. 1, ‘George Emil Palade’ University of Medicine, Pharmacy, Sciences and Technology, 540142 Targu Mures, Romania
Published online on: February 4, 2022 https://doi.org/10.3892/etm.2022.11190
Article Number: 264
Copyright: © Muresan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Depression is a negative emotional state that may persist for short or long periods of time with varying severity. The aim of the present study was to evaluate the method by which bioresonance therapy can improve the severity of recurrent depressive disorder with moderate and mild episodes experienced by patients. Bioresonance therapy is a method of energy treatment that processes the electromagnetic information of the human body using a sensitive Mora Nova device using electrodes. In addition, this improvement was compared with the one obtained by applying monotherapy with selective serotonin reuptake inhibitors. The study included two groups of patients suffering from depression. The first group received bioresonance treatment for five weeks. The second group received either newly introduced or on‑going pharmacological treatment with selective serotonin reuptake inhibitor antidepressants, as monotherapy, for five weeks. An outcome measurement of severity was performed. Results revealed that, the score improvement on the Hamilton Scale, used for assessing depression and comprising 17 items, showed a mean of 3.1 [standard deviation (SD), 1.28] for the bioresonance group one and a mean of 2.2 (SD, 0.61) for the second group. The difference between the two data series was statistically significant (P<0.0001, Student's t‑test). As the bioresonance therapy outcome was higher than the selective serotonin reuptake inhibitor medication outcome, it can be concluded that bioresonance can reduce the severity of the patients facing recurrent depressive disorder with moderate and mild episodes. Furthermore, the reduction in severity for the bioresonance group compared with the antidepressant medication group was statistically significant.

View Figures

View References

1	Haller H, Anheyer D, Cramer H and Dobos G: Complementary therapies for clinical depression: An overview of systematic reviews. BMJ Open. 9(e028527)2019.PubMed/NCBI View Article : Google Scholar
2	American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 5th edition. American Psychiatric Association Press, Arlington, VA, pp155-188, 2013.
3	Rang HP, Dale MM, Ritter JM, Flower RJ and Henderson G: Rang and Dale's pharmacology. 7th edition. International Edition. British Library Cataloguing in Publication Data. Elsevier Inc., Edinburgh, pp553-583, 2012.
4	James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, Abbastabar H, Abd-Allah F, Abdela J, Abdelalim A, et al: Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: A systematic analysis for the global burden of disease study 2017. Lancet. 392:1789–1858. 2018.PubMed/NCBI View Article : Google Scholar
5	Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B, Olese J, Allgulander C, Alonso J, Faravelli C, et al: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 21:655–679. 2011.PubMed/NCBI View Article : Google Scholar
6	Malhi GS and Mann JJ: Depression. Lancet. 392:2299–2312. 2018.PubMed/NCBI View Article : Google Scholar
7	Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, Bruffaerts R, de Girolamo G, de Graaf R, Gureje O, et al: Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet. 370:841–850. 2007.PubMed/NCBI View Article : Google Scholar
8	Pihtili A, Galle M, Cuhadaroglu C, Kilicaslan Z, Issever H, Erkan F, Cagatay T and Gulbaran Z: Evidence for the efficacy of a bioresonance method in smoking cessation: A pilot study. Forsch Komplementmed. 21:239–245. 2014.PubMed/NCBI View Article : Google Scholar
9	Gottfried C: The new diagnostic system by Dr. Cornelissen. IMZ Akademie, pp157-171, 2007.
10	Med-Tronik GmbH: Manual of instructions. Version 3.1.3. Med-Tronik GmbH, pp72, 2020.
11	Muresan D, Salcudean A, Sabau CD, Bodo CR and Gabos Grecu I: Bioresonance therapy may treat depression. J Med Life. 14:238–242. 2021.PubMed/NCBI View Article : Google Scholar
12	Med-Tronik GmbH: Nova MED Training&Therapy Manual, medical technology in the 21st century. Med-Tronik GmbH, pp16-37, 2014.
13	Muresan D, Salcudean A, Barbu BV, Bodo CR and Gabos GI: Evaluation of an alternative depression therapy using bioresonance. J Interdiscip Med. 6:82–86. 2021.PubMed/NCBI View Article : Google Scholar
14	O’Donnell JM, Bies RR and Shelton RC: Drug therapy of depression and anxiety disorders. Chapter 15. In: Goodman and Gilman’s pharmacological basis of therapeutics, 13th edition. Brunton LL, Hilal-Dandan R, Knollmann BC (eds). McGraw-Hill, New York, ΝΥ, pp267-277, 2001.
15	Stahl SM: Selectivity of SSRIs: Individualising patient care through rational treatment choices. Int J Psychiatry Clin Pract. 8 (Suppl 1):S3–S10. 2004.PubMed/NCBI View Article : Google Scholar
16	Zimmerman M, Martinez HJ, Young D, Chelminski I and Dalrymple K: Severity classification on the Hamilton depression rating scale. J Affect Disord. 150:384–388. 2013.PubMed/NCBI View Article : Google Scholar
17	Freeman MP: Complementary and alternative medicine (CAM): Considerations for the treatment of major depressive disorder. J Clin Psychiatry. 70 (Suppl 5):S4–S6. 2009.PubMed/NCBI View Article : Google Scholar
18	Lake J and Turner MS: Urgent need for improved mental health care and more collaborative model of care. Perm J. 21:17–024. 2017.PubMed/NCBI View Article : Google Scholar
19	Trifu S, Sevcenco A, Stănescu M, Drăgoi AM and Cristea BM: Efficacy of electroconvulsive therapy as a potential first-choice treatment in treatment-resistant depression (Review). Exp Ther Med. 22(1281)2021.PubMed/NCBI View Article : Google Scholar
20	Nguyen J: A literature review of alternative therapies for postpartum depression. Nurs Womens Health. 21:348–359. 2017.PubMed/NCBI View Article : Google Scholar
21	Badtieva VA, Pavlov VI, Khokhlova MN and Pachina AV: The application of bioresonance therapy for the correction of the overtrained athlete syndrome. Vopr Kurortol Fizioter Lech Fiz Kult. 95:51–57. 2018.PubMed/NCBI View Article : Google Scholar : (In Russian).
22	Nienhaus J and Galle M: Placebo-controlled study of the effects of a standardized MORA bioresonance therapy on functional gastrointestinal complaints. Forsch Komplementmed. 13:28–34. 2006.PubMed/NCBI View Article : Google Scholar : (In German).
23	Elio C, Guaitolini E, Paccasassi S, Rosati N and Cavezzi : Application of microcurrents of bioresonance and transdermal delivery of active principles in lymphedema and lipedema of the lower limbs: A pilot study. G Ital Dermatol Venereol. 149:643–647. 2014.PubMed/NCBI
24	Islamov BI, Funtikov VA, Bobrovskiĭ RV and Gotovskiĭ YV: Bioresonance therapy in rheumatoid arthritis and heat shock proteins. Bull Eksp Biol Med. 128:525–528. 1999.PubMed/NCBI(In Russian).